AYOXXA
LIVE

Serial Number

79224525

Owner

AyoxxA Biosystems GmbH

Attorney

Joyce von Natzmer

Filing Date

Oct 6, 2017

Add to watchlist:

No watchlists yet
View on USPTO

AYOXXA Trademark

Serial Number: 79224525 • Registration: 5705785

AYOXXA is a trademark filed by AyoxxA Biosystems GmbH on October 6, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

AyoxxA Biosystems GmbH (3 trademarks)

Nattermannallee 1
Köln 50829 , DE

Entity Type: 99

Trademark Details

Filing Date

October 6, 2017

Registration Date

March 26, 2019

Published for Opposition

January 8, 2019

Cancellation Date

October 10, 2025

Goods & Services

Pharmaceutical preparations for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; veterinary pharmaceutical preparations for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; diagnostic agents for medical purposes; diagnostic agents for veterinary purposes; chemical and biochemical preparations for medical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; chemical and biochemical reagents for medical purposes; chemical and biochemical preparations for veterinary purposes, namely, for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; chemical and biochemical reagents for veterinary purposes; chemical and biochemical preparations for pharmaceutical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; chemical and biochemical reagents for medical or veterinary pharmaceutical purposes; biological agents for laboratory analyses for medical purposes, namely, peptides, proteins and nucleic acids used as diagnostic agents for medical purposes; biological agents for laboratory analyses for veterinary purposes, namely, peptides, proteins and nucleic acids used as diagnostic agents for veterinary purposes; chemical and biochemical preparations and reagents for medical purposes, namely, for use in DNA analyses; chemical and biochemical preparations for blood tests for medical purposes; chemical and biochemical reagents for blood tests for medical purposes; chemical and biochemical preparations for blood tests for veterinary purposes; chemical and biochemical reagents for blood tests for veterinary purposes; peptides, proteins, nucleic acids and other biomolecules, or complexes of these molecules, for medical purposes, namely, synthetic or natural peptides, proteins, allergens, metabolites or nucleic acids for the treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases, protein arrays for medical diagnosis purposes, nucleic acid sequences for medical diagnosis purposes; proteins, nucleic acids and other biomolecules, or complexes of these molecules, for veterinary purposes, namely, synthetic or natural peptides, proteins, allergens, metabolites or nucleic acids for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations in animals, protein arrays for veterinary diagnosis purposes, nucleic acid sequences for veterinary diagnosis purposes; chemical and biochemical preparations and reagents for labelling of molecules for medical detection and monitoring purposes; chemical and biochemical preparations and reagents for labelling of molecules for veterinary detection and monitoring purposes

Filing History

CANCELLED SECTION 71
Oct 10, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 26, 2024 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Nov 1, 2019 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 16, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 25, 2019 FICS
FINAL DISPOSITION PROCESSED
Jul 25, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 26, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 26, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 8, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jan 8, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 19, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 14, 2018 CNSA
ASSIGNED TO EXAMINER
Oct 22, 2018 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 21, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 21, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 21, 2018 TROA
REFUSAL PROCESSED BY IB
Apr 6, 2018 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 22, 2018 RFCS
REFUSAL PROCESSED BY MPU
Mar 22, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 22, 2018 RFCR
NON-FINAL ACTION WRITTEN
Mar 21, 2018 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Feb 16, 2018 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2018 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2018 CNRT
ASSIGNED TO EXAMINER
Jan 16, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 16, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 4, 2018 REPR